The drugmaker shed billions of dollars in value after it told investors that widening Journavx’s approval to chronic pain ...

While the top- and bottom-line numbers for Vertex (VRTX) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to ...